KURE logo

KraneShares MSCI All China Health Care Index ETF (KURE) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

KURE, $ (piyasa değeri 0) fiyatla Financial Services işi olan KraneShares MSCI All China Health Care Index ETF'i temsil ediyor. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 44/100 (ihtiyatlı) olarak derecelendirilmiştir.

Son analiz: 16 Mar 2026
44/100 AI Puanı

KraneShares MSCI All China Health Care Index ETF (KURE) Finansal Hizmetler Profili

Halka Arz Yılı2018

KraneShares MSCI All China Health Care Index ETF (KURE) provides targeted exposure to the Chinese healthcare sector, tracking an index of free float adjusted market capitalization weighted companies. With a beta of 0.59 and assets under management of $0.08 billion, KURE offers investors a focused investment vehicle within the Chinese equity market.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 16 Mar 2026

Yatırım Tezi

KURE presents a focused investment opportunity in the Chinese healthcare sector, driven by the increasing demand for healthcare services in China. The fund's strategy of mirroring the MSCI All China Health Care Index provides targeted exposure to this growth. Key value drivers include the expansion of China's healthcare infrastructure and increasing healthcare spending. Potential catalysts include regulatory reforms favoring the healthcare sector and advancements in medical technology within China. However, investors may want to evaluate risks such as regulatory changes, geopolitical tensions, and market volatility affecting Chinese equities. With a beta of 0.59, KURE exhibits lower volatility compared to the broader market.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • The fund invests at least 80% of its net assets in instruments in its underlying index.
  • The underlying index is a free float adjusted market capitalization weighted index.
  • The fund is designed to measure the equity market performance of Chinese companies in the healthcare sector.
  • The fund is non-diversified.
  • The fund has a beta of 0.59, indicating lower volatility compared to the market.

Rakipler & Benzerleri

Güçlü Yönler

  • Targeted exposure to the Chinese healthcare sector.
  • Replication of a well-known index (MSCI All China Health Care Index).
  • Established brand recognition as a KraneShares ETF.
  • Relatively low beta of 0.59.

Zayıflıklar

  • Non-diversified nature increases risk.
  • Concentration in a single country (China) exposes it to geopolitical risks.
  • Dependence on the performance of the Chinese healthcare sector.
  • Small market cap of $0.08B may limit liquidity.

Katalizörler

  • Ongoing: Expansion of China's healthcare infrastructure.
  • Ongoing: Increasing demand for specialized healthcare services.
  • Ongoing: Technological advancements in healthcare.
  • Ongoing: Regulatory support for healthcare innovation in China.

Riskler

  • Potential: Regulatory changes in China affecting the healthcare sector.
  • Potential: Geopolitical tensions between China and other countries.
  • Potential: Economic slowdown in China.
  • Ongoing: Competition from other ETFs and investment funds.

Büyüme Fırsatları

  • Increased Healthcare Spending in China: China's healthcare expenditure is projected to grow significantly, driven by an aging population and increasing urbanization. This growth translates to greater demand for healthcare services and products, benefiting companies within the KURE index. The Chinese government's focus on improving healthcare access and quality further supports this trend. This represents a long-term growth opportunity for KURE, aligning with the overall expansion of the Chinese healthcare market.
  • Technological Advancements in Healthcare: The integration of technology into healthcare, such as telemedicine, AI-driven diagnostics, and digital health platforms, is transforming the industry. Chinese healthcare companies are increasingly adopting these technologies to improve efficiency and patient outcomes. KURE's exposure to these innovative companies positions it to benefit from the technological advancements reshaping the healthcare landscape. This ongoing trend offers a sustained growth opportunity for the fund.
  • Regulatory Support for Healthcare Innovation: The Chinese government is actively promoting innovation in the healthcare sector through supportive policies and funding initiatives. These measures aim to foster the development of new drugs, medical devices, and healthcare services. KURE's holdings in companies engaged in research and development activities stand to gain from this regulatory support. This ongoing government backing creates a favorable environment for growth within the Chinese healthcare sector.
  • Expansion of Healthcare Infrastructure: China is investing heavily in expanding its healthcare infrastructure, including hospitals, clinics, and research facilities. This expansion creates opportunities for healthcare companies to provide equipment, supplies, and services to these new facilities. KURE's exposure to companies involved in the development and operation of healthcare infrastructure positions it to capitalize on this growth. This long-term infrastructure development supports sustained growth for the fund.
  • Increasing Demand for Specialized Healthcare Services: As China's middle class grows, there is increasing demand for specialized healthcare services, such as cancer treatment, cardiovascular care, and geriatric care. Chinese healthcare companies are expanding their offerings in these areas to meet this growing demand. KURE's exposure to companies providing specialized healthcare services allows it to benefit from this trend. This ongoing shift towards specialized care creates a valuable growth opportunity for the fund.

Fırsatlar

  • Growth in the Chinese healthcare market due to aging population.
  • Increasing demand for specialized healthcare services.
  • Technological advancements in healthcare.
  • Regulatory support for healthcare innovation in China.

Tehditler

  • Regulatory changes in China affecting the healthcare sector.
  • Geopolitical tensions between China and other countries.
  • Economic slowdown in China.
  • Competition from other ETFs and investment funds.

Rekabet Avantajları

  • Specialized focus on the Chinese healthcare sector.
  • Replication of the MSCI All China Health Care Index.
  • Established track record in the Chinese equity market.
  • Brand recognition as a KraneShares ETF.

KURE Hakkında

KraneShares MSCI All China Health Care Index ETF (KURE) is designed to provide investors with exposure to the healthcare sector within the Chinese equity market. The fund operates by investing at least 80% of its net assets, plus borrowings for investment purposes, in instruments that mirror its underlying index or possess similar economic characteristics. This underlying index is meticulously constructed as a free float adjusted market capitalization weighted index, adhering to the 10/40 Constraint, which is a diversification rule limiting the weight of any single component. KURE's primary objective is to closely track the equity market performance of Chinese companies operating in the healthcare sector, offering a focused investment tool for those seeking to capitalize on the growth and potential of China's healthcare industry. The fund is non-diversified, meaning it invests a larger percentage of its assets in a smaller number of issuers compared to a diversified fund.

Ne Yaparlar

  • Invests in a portfolio of Chinese healthcare companies.
  • Tracks the MSCI All China Health Care Index.
  • Provides exposure to the Chinese healthcare sector.
  • Offers a focused investment vehicle for Chinese equities.
  • Replicates the performance of the underlying index.
  • Operates as a non-diversified fund.

İş Modeli

  • Generates revenue through management fees.
  • Invests in Chinese healthcare companies.
  • Tracks the MSCI All China Health Care Index.
  • Provides a vehicle for investors to access the Chinese healthcare market.

Sektör Bağlamı

KURE operates within the asset management industry, specifically focusing on providing access to the Chinese healthcare sector. The global asset management industry is experiencing growth, driven by increasing demand for specialized investment products. The Chinese healthcare market is expanding due to factors such as an aging population and rising income levels. KURE competes with other ETFs and investment funds offering exposure to Chinese equities and the healthcare sector. Competitors include funds with broader mandates or different weighting methodologies.

Kilit Müşteriler

  • Institutional investors seeking exposure to Chinese healthcare.
  • Retail investors interested in the Chinese equity market.
  • Financial advisors looking for specialized investment products.
  • Pension funds and endowments seeking diversification.
AI Güveni: 71% Güncellendi: 16 Mar 2026

Finansallar

Grafik & Bilgi

KraneShares MSCI All China Health Care Index ETF (KURE) hisse senedi fiyatı: Price data unavailable

Son Haberler

KURE için son haber bulunmamaktadır.

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

KURE için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

KURE için Wall Street fiyat hedefi analizi.

MoonshotScore

44/100

Bu puan ne anlama geliyor?

MoonshotScore, KURE'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

Yatırımcılar KraneShares MSCI All China Health Care Index ETF (KURE) Hakkında Ne Soruyor

KURE için değerlendirilmesi gereken temel faktörler nelerdir?

KraneShares MSCI All China Health Care Index ETF (KURE) şu anda yapay zeka skoru 44/100, düşük puanı gösteriyor. Temel güçlü yan: Targeted exposure to the Chinese healthcare sector.. İzlenmesi gereken birincil risk: Potential: Regulatory changes in China affecting the healthcare sector.. Bu bir finansal tavsiye değildir.

KURE MoonshotScore'u nedir?

KURE şu anda MoonshotScore'da 44/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

KURE verileri ne sıklıkla güncellenir?

KURE fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler KURE hakkında ne diyor?

KURE için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

KURE'a yatırım yapmanın riskleri nelerdir?

KURE için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Regulatory changes in China affecting the healthcare sector.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

KURE'ın P/E oranı nedir?

KURE için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için KURE'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

KURE aşırı değerli mi, yoksa düşük değerli mi?

KraneShares MSCI All China Health Care Index ETF (KURE)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

KURE'ın temettü verimi nedir?

KraneShares MSCI All China Health Care Index ETF (KURE) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • The information provided is based on available data and may be subject to change.
  • AI analysis is pending for KURE.
Veri Kaynakları

Popüler Hisseler